Skip to main content

Table 2 General characteristics IMM studies wherein patients were treated with SBRT

From: Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review

Author and year

Mean tumor volume in cubic centimeter

Treatment modality

Dose/fraction

Median follow-up

Overall survival

Clinical outcome

Radiological outcome

Toxicities

Shin, 2009 [15]

1.52

LINAC

14 Gy (10–16 Gy) / 1 fraction

10 months

8 (2–19) months

Improvement: 80%, Stable: 10%, Worse: 10%

Complete: 22%, Partial: 33%, Stable: 33%, Progression: 11%

None

Parikh, 2009 [9]

NA

CK

15 Gy/3 fractions

26 months

9,8 months

Improvement

Stable

None

Dewas, 2011 [10]

NA

CK

20 Gy / 4 fractions

11 months

NR

Stable

Stable

None

Lieberson, 2012 [11]

NA

CK

27 Gy / 3 fractions

3 months

15 months

Stable

Complete

None

Veeravagu, 2012 [16]

1.17

CK

21 Gy (14–27 Gy) / 3 fractions (1–5)

NR

2 months

Improvement: 11%, Stable: 44%, NA: 55%

Partial: 22%, Stable: 22%, NA: 78%

None

Mori et al., 2016 [12]

NA

VMAT

39 Gy / 13 fractions

5 months

NR

Improvement

Partial

None

Garcia, 2016 [13]

0.167

CK

17 Gy / 1 fraction

37 months

8 months

Improvement

Stable

None

Barrie, 2019 [14]

NA

CK

25 Gy / 5 fractions

26 months

8 (0–65) months

Stable

Progression

None

Ehret, 2021 [17]

1.1

CK

16 Gy (6–24 Gy) / 1 fraction (1–3)

8.5 months

11,7 months

Improvement: 27%, Stable: 30%, Worse: 21%

Complete: 79% patients with follow-up imaging

None

Our series, 2021

 

CK

30 Gy (25–36 Gy) / 6 fractions (5–6)

23 months

NR

Improvement: 40%, Stable: 60%

Complete: 25%, Partial: 50%, Stable: 25%

None

  1. Abbreviations: CK, CyberKnife®; Gy, gray; NA, not available; NR, not reach